American Heart Association

circhf-waveforms

About circhf-waveforms

This author has not yet filled in any details.
So far circhf-waveforms has created 47 entries.

Disparities in Rates of Admission to Primary Cardiology Service Among Black and Latinx Patients

Contributor: Sadaf Sharfaei

Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center

Study Link: Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center

Adenosine-induced vasodilation is impaired and may be a therapeutic target in HFpEF

Contributor: Seyedeh Maryam Hosseini, MD

Heart failure with preserved ejection fraction is characterized by impaired cardiovascular reserve and coronary microvascular dysfunction. Tissue hypoxia activates endogenous adenosine secretion leading to vasodilation of the myocardial microvasculature. By increasing tissue perfusion in working myocardium, adenosine responds to increased metabolic demand. Davila et al. demonstrate that this adenosine vasodilation mechanism is impaired in HFpEF due to up-regulation of the adenosine kinase (ADK) enzyme gene. ADK changes adenosine to its inactive form. Increasing endogenous adenosine by inhibiting the ADK enzyme pharmacologically may have therapeutic potential to improve coronary vasodilation, myocardial perfusion and LV diastolic dysfunction in HFpEF.

VITALITY-HFpEF: Designed to test the hypothesis that vericiguat may improve physical functioning in patients with HFpEF

Contributor: Emily Cendrowski

VITALITY-HFPEF is a trial underway which will evaluate the efficacy of vericiguat in HFpEF patients by using the KCCQ-PLS (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score) as a primary endpoint. The choice of this primary endpoint will make it the first HF trial utilizing a quality of life, patient-reported outcome (PRO) as a primary endpoint. There remains a need for medications which improve mortality and functional status for patients with HFpEF. An ongoing area of research involves the cyclic guanosine monophosphate (cGMP) pathway.

Visual Abstract: Endothelial Function with Continuous-Flow LVADs

Contributors: Ike Chinyere and Chase Stroud, MD

Effect of Continuous-Flow Left Ventricular Assist Device Support on Coronary Artery Endothelial Function in Ischemic and Nonischemic Cardiomyopathy

Study Link: Effect of Continuous-Flow Left Ventricular Assist Device Support on Coronary Artery Endothelial Function in Ischemic and Nonischemic Cardiomyopathy

Proenkephalin: a novel marker of renal dysfunction in heart failure

Contributor: Nicole Smith

Is the opioid system responsible for deteriorating renal function in heart failure?

In a large chronic HF study population, Emmens and colleagues demonstrated higher levels of the opioid surrogate proenkephalin (PENK) are associated with worse HF and deterioration of kidney function. Could PENK be the next renal biomarker in heart failure?